Pacira BioSciences, Inc.
PCRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1,135 | $1,086 | $1,150 | $870 |
| - Cash | $148 | $300 | $284 | $277 |
| + Debt | $10 | $631 | $636 | $639 |
| Enterprise Value | $997 | $1,417 | $1,503 | $1,232 |
| Revenue | $180 | $181 | $169 | $187 |
| % Growth | -0.9% | 7.2% | -9.8% | – |
| Gross Profit | $145 | $140 | $135 | $147 |
| % Margin | 80.9% | 77.4% | 79.7% | 78.7% |
| EBITDA | $34 | $29 | $34 | $51 |
| % Margin | 19.1% | 16.1% | 19.9% | 27% |
| Net Income | $5 | -$5 | $5 | $16 |
| % Margin | 3% | -2.7% | 2.8% | 8.6% |
| EPS Diluted | 0.12 | -0.11 | 0.1 | 0.34 |
| % Growth | 209.1% | -210% | -70.6% | – |
| Operating Cash Flow | $61 | $12 | $35 | $33 |
| Capital Expenditures | -$4 | -$3 | -$9 | -$2 |
| Free Cash Flow | $57 | $9 | $27 | $31 |